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Abstract: Background: The pharmaceutical sector undertakes extensive research and development (R&D). Pharmaceutical 
industries have continued to launch an appreciable number of new medicines, different pharmaceutical formulations, new indications 
and other innovations that contribute to the growth of this sector. New novel medicines are increasingly essential for continued success 
given the number of standard medicines now available as low cost generics or biosimilars. Consequently, innovation is a fundamental 
element in pharmaceutical company competition. Not all innovations though are the same size, type or category with differentiation of 
innovation essential for commercial success. However, given the wide range of definitions used in the literature, the framing may diffuse. 
Currently, there are several types and categories of innovation are deficiently harmonized and poorly stratified resulting in analysis 
trends and provide major obstacles to innovation’s differentiation and in assessing the company's innovative dominant characteristic in 
the sector. The objective of this study is to stratify and organize, didactically, the field of definitions and concepts of innovation and 
provide a structural and operational delineation, from a critical point of view, for the classifications of innovation applied to the 
pharmaceutical industry. 
Keywords: Innovation, Pharmaceutical science, Pharmaceutical novelties, Pharmaceutical technology. 
 
1. Introduction and theorical framework 
The pharmaceutical sector is the sector that invests most in 
Research and Development (R&D) and one of the most 
innovators in the market [1] when compared to other segments. 
Many diseases now have effective treatments to reduce 
morbidity and mortality as well as increase the quality of life 
and life expectancy [2]-[3]. In particular, the 1990s yielded 
several successful medicines which empowered the 
pharmaceutical sector and its shareholders [2]. 
According to Craig and Malek [4], the pharmaceutical 
industry has an important role to play in society. This 
importance stems from the joint responsibility with the medical 
profession for the maintenance of health, which, in itself, is 
already a valuable asset, as well as enhancing productivity. 
This is expected to continue with the discovery and 
development of new medicines to treat areas of unmet need [5]-
[6]. In addition, innovations are essential for the continued 
success of pharmaceutical companies with the increasing 
availability of standard medicines as low cost generics and 
biosimilars [7] although this can be hard to achieve [8]-[9]. 
According to Achilladelis and Antonakis [10], innovation is 
a dynamic process building on the comments of Pavitt [11] that 
“industrial firms cannot and do not identify and evaluate all 
innovation possibilities indifferently, but are constrained in 
their search in their search by their existing knowledge and 
skills to closely related zones". That is the tendency that a 
particular industry specializes in a particular type of 
innovation, having more prominent characteristics for a 
particular category when compared to others. 
Inventions or Technological discoveries applied and 
marketed can be grouped into different categories. However, 
due to the myriad of definitions for the types of innovation, 
there is ambiguity in perception and demarcation of these 
categories [12]. Defining the concept and categorizing the 
types of innovation is important to establish ways of 
operationalizing the terminology and their application in 
different segments [12]. This allows the establishment of 
standards that can sustain scientific, technological, economic 
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and industrial comparisons. It is only possible to expand 
knowledge about a potential innovation framework as the 
conceptual application is consolidated, giving rise to a common 
starting point for classifications. 
The objective of this study is to stratify and organize the 
different fields and concepts of innovation, as well as to 
provide a structural and operational delineation, for the 
different innovations from pharmaceutical companies. 
Concomitantly, by elaborating a guidance structure for the 
different classifications, we intend to demonstrate how 
innovation relates to pharmaceutical companies and how the 
typological profile described in the literature can be framed to 
examples of new innovations. This builds on the concept from 
the OECD [13] that the minimum requirement for an 
innovation is that the product, process, marketing or 
organizational method should be new, or significantly 
improved for the company. Consequently, the perspective 
adopted to evaluate the innovative act, and assign a 
categorization in this paper, is an entrepreneurial one, 
specifically from the point of view of pharmaceutical 
companies. This is particularly important at this time as there 
are concerns with the funding of new medicines in a number of 
countries due to ongoing pressures from ageing populations, 
stricter treatment targets and the continued launch of new 
premium priced medicines especially in areas of cancer and 
orphan diseases [8]-[14]-[15]-[16]-[17]-[18]. There are also 
concerns among European health authorities for proposals to 
accelerate the introduction of new premium priced medicines – 
adaptive pathways – without adequate and accepted definitions 
of innovation and unmet need among all key stakeholder 
groups [19]. Having said this, a number of European countries 
base their discussions with pharmaceutical companies on the 
potential prices of new medicines on their perceived level of 
innovation versus current standards without necessarily stating 
the methodology used for defining the different levels of 
innovation [20]-[21]-[22]-[23]. Their deliberations are 
subsequently heavily scrutinized by pharmaceutical companies, 
but are usually endorsed [22]-[23]-[24]. 
2. Innovation 
As defined by OECD [13] innovation is the implementation of 
a new or significantly improved product (good or service), or 
process, a new marketing method, or a new organizational 
method in business practice, workplace organization or in 
external relations [13]. Innovation is not necessarily a given 
from a creation or invention. Novelty implementation must 
reach the final commercial design to be characterized as an 
innovation. In addition, the search for a competitive differential 
is essential to define what an innovation is. Consequently, an 
innovation is compounded by the application of what is new, 
aiming to seek competitive differentials from current treatment 
approaches in the case of new medicines. 
It is interesting to highlight that innovative activities are 
fundamental forces for the introduction of competitive 
differentials. According to Kurz [25], producers are 
encouraged to introduce new methods, new types or products in 
order to move away from competitors in certain markets. 
Conforming to this [25], competition means rivalry in which 
only the successful innovators will survive. Consequently, the 
ability to innovate is essential to maintain competitive 
advantage and for the survival of modern corporations [26]. 
Kim and Lui [27] emphasize that innovation has been 
considered as one of the most important factors in 
strengthening companies‟ competitiveness. The highlight for an 
innovative company is the development of new products with a 
high innovation load, which forces the discontinuity of other 
products, i.e. disinvestment in these [28], or their reduced use. 
Alternatively, providing an improved attribute such as 
improved quality of care leading to an improved financial 
result.  
As a result, improving the performance of a pharmaceutical 
company through gaining a competitive advantage, or keeping 
this advantage, is the goal of launching new products. This can 
be achieved, for example, with innovations that provide new 
products, new uses or combinations, increased product quality, 
open new markets, as well as reduce unit production costs, 
purchase costs, distribution or transportation costs [13]-[29]. 
Innovation actions may vary from one implementer to another, 
because some can expend efforts on more significant 
innovations, and others could be interested only in developing 
what is common to the market but new to the implementer, 
providing more restricted competitive gains. 
Evolutionary theories have sustained broad support for the 
theory of innovation; however, it is seen that in neoclassical 
doctrine a refinement of theories has been identified and 
postulated by the inclusion of approaches such as competition, 
games and decision making, besides traditional Schumpterian 
approaches, such as industrial evolution and transformation 
[26]-[30]. The search of an advantage by companies is essential 
for those with innovative characteristics, in addition to the 
motivation inherent to the entrepreneur to launch something 
very new to achieve success. Kenney [31] emphasizes and 
divides motivations into: i) financial success with high capital 
gains or corporate profits; and ii) the enormous desire to 
succeed and win. 
According to Futia [32], the main incentive resulting from 
R&D activity by individual companies is the perspective of 
changing the structure of the market and gaining market power 
through successful and decisive innovations. Despite this, 
investment in innovation is a resource allocation that involves 
strategic evaluation allied to technological, market and 
competitive uncertainties [33]. 
Innovation has become fundamental to achieve prominence 
and even greater importance from global competition [34]-[35]. 
In view of this, we believe it is necessary to adapt to the 
definition of innovation, considering that innovation is the 
provision of a new goods or new service/process/methodology 
or improvements in existing ones, searching to obtain a result 
that gives prominence and a competitive advantage to 
pharmaceutical companies. 
3. Methods 
An exploratory research was carried out, highlighting certain 
phenomena and aspects that contribute to the understanding of 
the investigated background [36]. Searches were carried out in 
4 databases: SCOPUS, PubMed, Web of Science and Science 
direct. Articles published up to 2015 were selected, including 
those available online in 2015 with publication scheduled for 
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2016, in English and Portuguese. Terms used in the searches 
were related to innovation. The main descriptors used were: 
novelties, innovation, innovator, innovation policy and 
innovation diffusion; and they were conjugated to the terms: 
marketing, processes, services, management, organization, 
administrative, pharmaceutical technology, pharmaceutical 
processes, pharmaceutical industry, pharmaceutical chemistry, 
pharmaceutical marketing and medicines. Using a qualitative 
approach, which according to Vieira and Moraes [37] provides 
a greater flexibility for theory‟s adaptation of the phenomenon 
to a structural model of classification, an innovation 
hierarchical profile was delineated. Information used in this 
study was collected to aid the design and relationships between 
terminologies, as well as to base definitions and classifications 
with actual examples of innovations in the pharmaceutical 
industry [38]. 
4. Innovation types and subtypes 
4.1. TYPOLOGY 
According to OECD [13], Joseph Schumpeter identified five 
types of innovation: introduction of new products, introduction 
of new processes or production methods, opening of new 
markets, development of new chain‟s supplies resources and 
creation of new market structure in industry [13]-[35]-[39]. In 
this context, it is perceived that innovation transposes to 
basically technological issues and incorporates non-
technological characteristics [13]-[40]. As reported by Souto 
[29], it is possible to distinguish technological and non-
technological innovations within different contexts. It means 
that is reasonable to consider them as two large dimensions 
[29]. Among them, conforming to figure 1, four types stand 
out, considering the "schupeterian" categories adapted [13]; 
which are: (i) Product Innovation; (ii) Process Innovation; (iii) 
Marketing innovation; (iv) Organizational innovation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Representation of types of innovation integrated to 
technological and non-technological dimensions. Pentagons 
represent the dominance of innovation‟s types. The elliptical 
structure represents technological tendency or not of an 
innovation. 
 
Product innovation is strongly, but not exclusively, linked to 
the concept of technological innovation. Product innovations 
may use new knowledge, technologies, or may be based on new 
uses or combinations of existing knowledge and technologies. 
These include the introduction of new products and significant 
improvements in functional or use characteristics of existing 
goods and services [13]. However, a new product for a 
company will not always be a new product on the market. 
There is the option for the company to develop new products 
for its portfolio, being a novelty for the company, but not for 
the market. This development can improve business 
performance [41]. 
In the pharmaceutical industrial segment, an example of such 
an innovation was introduction of monoclonal antibodies 
(mAbs). In 1975, Köner and Milstein [42] identified that it was 
possible to hybridize antibody-producing cells of diverse 
origins that could be provide specific medical products of 
importance. In 1986, the first monoclonal antibody, 
muromonab-CD3, was launched. It was approved for the 
prevention of liver transplant rejection [43]-[44]. Since then, 
the study of monoclonal antibodies as new therapeutic 
approaches has attracted considerable attention of the 
pharmaceutical industry, and these product innovations have 
been a considerable economic success [45]. For example, the 
utilization of the anti-TNF alpha medicines for use in 
rheumatoid arthritis has also grown appreciably in recent years 
in view of their effectiveness especially once concerns with 
their safety in routine clinical care had been addresses through 
registries [6]-[46]-[47]-[48]-[49].  
In addition, thiazide diuretics have been, for a long time, first 
line treatment for hypertension [50]. However, in 1981, the 
angiotensin converting enzyme inhibitors (ACEIs) became 
available and endorsed in the management of hypertension, 
especially in patients with concomitant diabetes to help prevent 
nephropathy [51]-[52]. More recently, angiotensin receptor 
blockers (ARBs) have been launched to reduce troublesome 
coughing in a minority of patients, with their use increasing 
with the availability of generic ARBs [53]-[54]. 
Another innovation was the launch of the first medicine for 
the treatment of peptic ulcers, cimetidine, which act as a 
selective antagonist of histamine (H2) receptors. This aroused 
the interest of other pharmaceutical companies in developing 
other H2 antagonists, employing the strategy of molecular 
modification, resulting in products known as “me too” [55]. 
The concept me too is historically simple and powerful to 
portray therapeutic molecules with similar mechanisms of 
action of those consecrated substances in the market [56]. 
Similar products included ranitidine, famotidine and nizatidine. 
Despite these new molecules being original and chemically 
distinct, they have a similar action when compared to the first 
drug released and the therapeutic class establisher [56]. This 
was followed by the development of the proton pump inhibitors 
starting with omeprazole, which subsequently displaced the H2 
antagonists and were again seen as an innovation [57]-[58]-
[59]-[60]. Again, other companies followed suit with the 
originator developing a follow-on compound – esomeprazole - 
to help minimize the revenue loss following the patent loss of 
omeprazole. This is called „evergreening strategies‟ [61].  
Other important developments include antibiotics, although 
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concerns now with the lack of new therapies [62]-[63]-[64]-
[65], as well as the development of new medicines to combat 
rejection following organ transplantation starting with 
cyclosporine, which has recently been shown to improve graft 
survival versus newer medicines such as tacrolimus [66]. More 
recently new medicines to combat hepatitis C have been 
developed offering the potential for a cure. However, concerns 
with their costs and potential budget impact, despite very low 
cost of goods, have impacted on their utilization [67]-[68]-[69]. 
Process innovation is defined as the introduction of new 
processes, operational procedures, equipment or resources that 
improve the performance of the method, production and 
distribution, as well as other methodologies or improvements of 
existing ones. Consequently, the implanted innovations, even in 
the form of optimization, are a way of reducing unit costs, 
production or delivery times, quality improvement, or to 
produce or distribute a new or significantly improved product. 
These types of innovations can confer differential 
competitiveness [13]. This type of innovation may also result in 
reduced inventories, scale change in economics, greater 
flexibility in the production line and minimization of 
infrastructure investments [70]. Consequently, new or 
optimized processes can be a corporate strategy to seek 
competitiveness, and this can be a central factor determining 
the success or failure of companies in long term [71]. An 
example of application of this typology is the process of 
obtaining erythropoietin, which has been optimized by going 
from the old batch manufacturing process in a bioreactor with 
controlled agitation to culture in semi-continuous perfusion in 
fluidized bed bioreactors, resulting in considerable productivity 
gains [72]. 
Marketing innovation is the implementation of an approach 
or monitoring method, improved or new, in the market. This 
can occur through significant changes in packaging design, 
product offerings, positioning, product promotion or pricing 
[13]. Results generated by this approach are aimed at 
improving customer needs or, as a way of positioning the brand 
or products to increase sales by opening new markets or by 
increasing commercial appeal such effervescent flavoured 
acetaminophen. This may include changes in packaging design, 
changes in marketing strategies, new media, credibility 
strengthening, and linking to welfare programs. 
According to Becker and Lillemark [73] within 
pharmaceutical industry, the development of new medicines 
through R&D is common, which still persists today [6]-[74], 
combined with the delivery of these products to the market. 
Typically, marketing departments have considerable budgets in 
comparison to other departments [75], enhancing the 
profitability of the sector [76]. The 1990s were marked by the 
idea of increasing marketing integration with other industry 
areas, creating a trend in the sector. This multidisciplinary 
integration was new in the pharmaceutical sector and had as its 
main motivation the beneficial economic effects on the 
performance of new product launches [73]-[77]. 
According to OECD [13] a change in the form and 
appearance of the product/service without changing functional 
characteristics and use constitutes a marketing innovation. In 
this paper, this statement is divided into: i) if the change in 
appearance, for example, the introduction of the brand in low 
relief in pills, which will be understood as an innovation in 
marketing because it is the simple business differentiation or 
embellishment of the product; on the other hand, ii) when the 
change goes beyond appearance, it is considered that this 
change is a differentiation of the product itself. An example of 
the latter is the change of a vial to a filled syringe that 
facilitates delivery of the drug. Alternatively, the development 
of a longer acting injectable formulation resulting in once a 
day, once a week, or once a month, to improve compliance or 
the development of a longer acting injection from an oral 
formulation to improve compliance as seen with the 
antipsychotic medicines [78]-[79]. In this case, it‟s understood 
that those constitutes a product innovation. Novelties 
introduced regarding issues of storage and the supply chain, but 
that do not generate improvements in dosage such as packaging 
with markers that make it difficult for counterfeiters, or that 
make the packaging becomes more enticing, are also 
understood as marketing innovations. 
Product‟s positioning through sales channels, billboards, 
magazines, advertising, television programs, internet media and 
other means of dissemination, even if subtle, can also be 
considered as new approaches, possibly characterized as 
marketing innovations. Another common strategy is to 
differentiate the price of medicines' brand and generic drugs by 
"value adding" to the brand [4] or to vary the price with the 
consumption as a result of the relation between demand and 
supply. This is more difficult with good quality generics with 
multiple publications showing no difference in effectiveness 
between the originator and generic across many drug classes, 
leading to for instance high voluntary International 
nonproprietary name (INN) prescribing in the UK [7]-[80]-
[81]-[82]-[83].  
Development and introduction of a new organizational 
procedure, not previously employed, is framed as 
organizational innovation [13]-[84]. This can cover several 
areas, such as financial, information technology, administrative, 
purchasing, and logistics, and should impart competitive 
differentiation related to increased performance or reduced 
operating costs. Camisón and Villar-López [85] emphasize 
what was evidenced by Hamel [86] that organizational 
innovation represents one of the most important and sustainable 
means of competitive advantage. The OECD [13] considers 
that other organizational changes, such as actions that improve 
workplace satisfaction with consequent productivity 
improvement, are also organizational innovations. 
Organizational innovations also encompass methodologies 
that increase the level of learning and knowledge sharing in an 
embracing way. For example, the implementation of computer 
systems such as ERP (Enterprise Resource Planning) that 
manage facilities' production and stock. Initiatives that 
establish new approaches with suppliers that can result in 
simpler and faster procedures are, also, widely used as 
organizational changes. 
Companies‟ mergers and acquisitions, common practice in 
the pharmaceutical segment as a competitive strategy, are also 
considered organizational innovations, but these may interfere 
with other forms of innovation such marketing. In this case, the 
framework is dependent on the main strategy for the merger. If 
the prevailing acquisition or merger strategy is to harmonize 
DOI: 10.18535/ijsrm/v5i7.20 
 
Wallace Mateus Prata, IJSRM Volume 5 Issue 07 July 2017 [www.ijsrm.in]   Page 5938 
organizational practices between two companies to give them 
greater competitive strength, acquiring technology or improved 
incorporating of a basket of products and processes, the main 
framework will be organizational. Although, if the reason is 
based on increasing marketing power, improving brand 
positioning, reliability or image, they are classified as a 
marketing innovation.  
As an example of this type of innovation, was the hostile 
takeover of Warner-Lambert's by Pfizer [87]. According to 
Kipp and Leiding [88], this type of acquisition was 
advantageous because Pfizer was able to implement operational 
and staff decisions without major concerns with institutional 
culture as the companies had been previously co-promoted 
products including atorvastatin. Another example was the 
outsourcing of data centers and help desks to increase 
efficiency and a major concentration of the consumer‟s health 
field by AstraZeneca with IBM [88]. The pharmaceutical 
industry had improved e-business with this development, 
classifying this as an organizational innovation contributing to 
a marketing innovation [85]. 
4.2. SUBTYPE 
Conceptually, according to Garcia and Calantone [12] new 
approaches are often classified in order to identify their 
innovative characteristics or the degree of innovation, with 
potentially 79 categories subdivided into five large groups.  
Denominations of each category differ in the form of 
understanding and according to the authors‟ interpretation. 
However, there is typically a lack of harmonization between 
authors regarding innovation typology. 
Higgins [89] suggests three levels of innovation: i) 
incremental and continuous improvements; ii) significant 
improvements, where new products are developed from 
existing ones; or iii) “big bang” innovations that transform the 
way products or services are perceived or appropriated for 
consumption. According to Cooper [90] due to many 
definitions of innovation, it is now widely accepted that 
innovation can be expressed in a number of ways. The most 
prominent forms are defined as radical, incremental, product, 
process, administrative and technological innovations. 
Saaksjarvi [91], categorizes innovations into three large types: 
i) continuous, in which small modifications occur in current 
products; ii) continuous dynamic, where there is the creation of 
a new product or modification of the existing ones; iii) and 
discontinuous, in which there is the creation of a new product 
previously unknown that requires learning. 
However, in our study, two distinct and sequential 
classifications (types and subtypes) are proposed and used. Our 
proposal is to first point out the type of innovation: product, 
process, marketing or organizational change and, subsequently, 
subcategorize these into subtypes, as shown in Figure 2. 
According to Sidin and Sham [92], there are three degrees of 
innovation, categorized as incremental, semi radicals and 
radicals. This contrasts with Garcia and Calantone [12] who 
suggest four types of innovation, i.e. radical innovation, really 
new, discontinuous and imitative. The classification 
emphasizes the degree of novelty involved, such as those that 
employ radical innovation at one end whilst imitative at the 
other, through incremental innovation or improvements. There 
is congruence among the innovation degrees‟ denominations 
highlighted by Sidin and Sham [92] and Garcia and Calantone 
[12] when discussing the pharmaceutical industry. 
Consequently, our proposed the subtypes are based on an 
adaptation of these two authors and include radical, semi-
radical, incremental and imitative (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Layering of dimensions, innovation types and 
subtypes integrated. 
4.2.1. Subtypes of product innovation 
Radical innovations reformulate behavior and the current 
structure of a market [12]. This contrasts with the definition 
employed by Leifer et al. [93] who suggested that radical 
innovation is realized through unique or significant 
improvements in existing resources and improve cost and 
product performance. The concept of Vasconcelos [94] defines 
radical innovation as a totally new product, with characteristics 
quite distinct from previous products, which requires new skills 
among both providers and customers. Radical innovations 
should incorporate a new technology or knowledge that results 
in a new market infrastructure. Radical is characterized by 
extreme differences from what is considered traditional or 
usual, and should lead to existing products becoming obsolete, 
i.e. disinvestment. 
Often though, radical novelties do not address a known 
requirement, but may create a demand previously unrecognized 
by the consumer. This new demand, for example, could be 
generated by the discovery of new medicines to address an 
unmet medical need, diseases that do not have available 
treatments, or through a pre-existing demand but with a new 
therapeutic approach that is considerably more effective or 
efficient resulting in substitution of current treatment 
approaches. A new drug that provides a preventive or curative 
effect is an excellent case of a radical innovation. Examples 
include vaccines against smallpox leading to the eradication of 
the disease [95]-[96]-[97], H2 antagonists appreciably reducing 
the need for operations for stomach ulcers and effectives cures 
for Hepatitis C [57]-[58]-[59]-[60]-[67]-[68]-[69].  
Another example, more recently, of radical innovation in 
pharmaceutical market was a sildenafil in 1998. This new drug 
provided a breakthrough for sexual medicine with a refined 
clinical approach to sexual health disorder. Before the release 
of this drug, treatment was performed with invasive 
applications of injectable alprostadil [98]. Sildenafil provided 
intense displacement with significant substitution of the 
previous drug, as well as creating new clients who started 
treatment due to the ease of oral therapy. Monoclonal 
antibodies are another example [6]-[43]-[44]-[45]-[46]-[47]-
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[48]-[49]. The selective serotonin re-uptake inhibitors (SSRIs) 
launched in 1987 are also an example as they helped to 
revolutionize the management of depression in ambulatory care 
[99]. Other examples include finasteride and tamoxifen in 1992 
[60].  
Garcia and Calantone [12] indicated that only 10% of all 
innovations fall into the category of radical innovations. In 
pharmaceutical industry, the proportion of radical innovations 
is now seen as even smaller [8]-[9]. Similarly, Kipp and 
Leiding [88] indicated that between 1989 and 1993, the Food 
and Drug Administration (FDA) approved 127 new molecular 
entities (excluding generic drugs), but only a minority offered a 
clear clinical advantage.  
Less rare are semi-radical innovations which are seen as new 
items combined with a market novelty that generate 
competition and displacement, but not discontinuity of other 
products. Examples of this are “me too” medicines, chemically 
distinct, but with mechanisms of action similar to the initial 
medicines in the class or related class. Examples include 
different Proton Pump Inhibitors (PPIs) and the Angiotensin II 
Receptor Blockers (ARBs) [54]-[100]-[101]. Examples of 
radical and semi-radical innovations include the statins. 
Lovastatin was approved in 1987 for treatment of 
hypercholesterolemia, with simvastatin approved in 1991, 
atorvastatin approved in 1996 and rosuvastatin approved in 
2003 [102]-[103]-[104]. Their appreciable impact on reducing 
coronary vascular (CV) events in high risk patients has resulted 
in their use in over 10% of some populations [101]. The advent 
of low cost generic atorvastatin is leading to recommendations 
in the UK to an appreciable increase in its dosing to further 
reduce CV morbidity and mortality [7]. Similar examples of 
radical and semi-radical innovations are the PPIs versus the H2 
blockers [57]-[58]-[59]-[60] with again high consumption in 
some countries [101].  
Despite this, there are many debates surrounding the 
essentiality of the “me too” therapeutic substances. Gagne and 
Choudhry [105] point out that market competition between 
similar drugs can reduce the cost of all drugs in the therapeutic 
class and improve accessibility for patients and healthcare 
systems. However, this is not typically the case and prices of 
medicines usually only decrease appreciably once there are 
generic products in a class coupled with reference pricing 
within the class [7]-[106]-[107]. In some cases, more options to 
prescribers may improve clinical outcomes since some 
medicines may have distinct efficiency or safety profiles for 
specific patients. This includes the anti-depressants and anti-
psychotics where typically treatments are tailored to individual 
patients with limited guidance from health authorities unless 
there are concerns with the cost-effectiveness of patented 
medicines including formulations in routine clinical care once 
low cost generics are available in the class or disease area 
[108]-[109]. There were concerns with the value of duloxetine 
in Sweden due to appreciably higher prices than generic 
venlafaxine and mirtazapine but concerns with its effectiveness, 
leading to prescribing restrictions [110]. However, a “me too” 
can foster competition between companies reducing their 
market shares, which is a powerful stimulus for research and 
development of new substances of therapeutic interest [104] to 
maintain shareholder interest. 
Insulin glargine, approved by FDA in 2000, is another 
potential case of semi-radical innovation. This medicine is the 
result of three modifications of human insulin produced by 
recombinant DNA technology [111]. However, there have been 
concerns with actual outcome differences between insulin 
glargine and NPH insulins, challenging the high prices for 
insulin glargine leading to calls to lower prices for continued 
reimbursement [112]-[113]. 
The incremental subtype covers products resulting from 
substitution or addition of a certain technical characteristic or 
necessary competence for the production or use of the product. 
In addition, resulting from a new specification of an already 
existing characteristic through an improvement in a product 
attribute without modifying the system as a whole [94]. The 
basic idea of this subtype is that the new medicine has 
improved properties leading to substitution of existing 
medicines over time. Vasconcelos [94] describes as an 
incremental concept the innovation by recombination, 
combining from different characteristics of products or new 
uses of existing products. These innovations have higher 
success rates with implementation and lower risks, effort and 
resources when compared to radical and semi-radical subtypes 
[92]. Some incremental innovations maybe so important that 
they can cause some market displacement, but they differ from 
semi-radical innovations because they are not entirely new, just 
modified. An example is the association of amoxicillin with 
clavulanate – co-amoxiclav [114].  
Other examples include coatings applied to pharmaceutical 
forms to protect them in the stomach and reduce side-effects as 
well as controlled drug release system to reducing dosing and 
improve compliance [115]-[116]-[117]. 
The last innovation‟s subtype, the imitative one, has many 
definitions as it is difficult to find a common definition for this 
classification, since innovation and imitation are at opposite 
ends. The only common feature of the various definitions is 
that innovation implies novelty and imitation refers to 
replicating or doing the same [34]-[118]. 
In this paper, innovation is considered to be everything that 
is new to the company and which gives a competitive 
advantage in the market. In this way, an imitation is in general, 
the quickest and easiest way to develop a product, which can 
confer a strategic differential. When linked to creative 
potential, imitations are capable of continuous and permanent 
improvements. Copying can be an excellent way to enter the 
market and stimulate an innovation environment, considering 
that innovation from the past is the starting point for future 
innovations. 
Imitations has been defined as the form of technological 
development that expands the existing set of knowledge base of 
the company, but not the world as a whole [34]-[164]-[165]. 
Imitations are, usually, low density novelties; however, they 
can provide appreciable influence in companies and countries 
that do not dominate a given technology.  The imitative 
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innovation is not incremental innovation, as shown by Garcia 
and Calantone [12] reaffirmed by Yu et al [118]. It is, in fact, 
an imitation, but used as a way to advance industrially in items 
with a high technological load which is little dominated and 
widespread in the world. Consequently, imitative innovation is 
not a simple routine copy, since it must be aggregated with 
little diffused technologies. 
Instead of visualizing antagonistic imitation and innovation, 
we suggest the existence of an interface between purist 
imitation, imitative innovation, and innovation (Figure 3). To 
develop this context, imitation tends to be a routine copy, with 
no appreciable processing knowledge by the company that 
executes it. Examples of "purist" copies of medicines are 
generics and biosimilars. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Pyramid of interface between purist imitation, 
imitative innovation and innovation. Arrows indicate the 
ascendancy and possible transposition of levels due to the 
technological knowledge, financial contribution, culture of 
stimulus to creativity, business strategy for innovation and 
methods and processes knowledges. 
 
However, it is recognized that the development of 
biosimilars requires a higher degree of knowledge and 
technology versus small oral molecules [119]. Ongoing studies 
are also needed to help dispel myths regarding the effectiveness 
and safety of biosimilars versus originators [120]. The 
imitating action allows companies to change their position, 
gradually, through the strengthening of technological 
knowledge, and in a timely manner, having improved 
conditions and capacity to innovate. Yu and researchers [118] 
point out that China's innovative capacity has increased 
significantly since 2001, demonstrating the transition between 
innovative profiles. 
With imitative practice, the company acquires 
manufacturing‟s know-how and, in the future, can perform 
incremental improvements in the product or process. Overall, 
imitative innovations have smallest risks of failure, since being 
a fast copier is a reliable strategy, with cost advantages and risk 
minimization [118]. Consequently, the imitative subtype 
innovation should not be underestimated as it may cause 
subdivision and displacement of markets, significantly altering 
their direction [12], with the first innovative company 
potentially suffering immediate economic impacts with 
imitation.  
4.2.2. Subtypes of Process Innovation 
Conceptually, the radical subtype of process innovation is very 
similar to that of product innovation, with the safeguard of 
being applied to methods, procedures and operations to obtain 
a result. A radical innovation of the manufacturing process is, 
usually, linked to a new product of the radical subtype, as in the 
case of insulin development. Initially, insulin was derived from 
swine, bovine or equine pancreas. In the late 1970s and early 
1980s, researchers cloned the genes of Human Insulin and 
expressed it in Escherichia coli. Recombinant insulin has now 
become the main source of insulin [121]-[122] leading to 
discontinuation of animal pancreas products [121]-[123]. As 
mentioned earlier, the modification in the production of EPO is 
another generating industrial gain [72].  
Another semi-radical process innovation was the 
introduction of direct compression for tablet production. As a 
result, wet production processes are slowly being replaced by 
direct compression to improve production efficiency [124]-
[125]-[126]-[127]-[128]-[129]. 
The incremental category is resulting from the substitution or 
addition of a given technological resource, equipment or 
methodology that impacts on reducing costs, improves yields 
and one that is faster in obtaining the final product. In light of 
this, these new developments can be understood as creative 
measures to reduce production set-up times, to develop tool 
exchanges with quick coupling to speed the machine‟s 
adjustment time and to develop new procedures, methods and 
processes to streamline manufacturing to give greater 
production performance.  
The increasing need for faster and more effective analytical 
methods for quality control employment has boosted research 
in this area with the consequent development of Ultra High 
Performance Liquid Chromatography (UHPLC) equipment. 
This equipment with advanced systems and technology in the 
pump, detector and automatic sampler represented an 
incremental innovation in the process of physical-chemical 
analysis [130]-[131]. 
Companies dedicated to develop new technology, such as 
bioprocesses, usually do not have access to original drug 
protocols of production, since such information is usually 
restricted. Consequently, in the case of biosimilars, 
manufacturing processes will be mixed, adding imitative and 
incremental steps to the origin process. For instance, infliximab 
CT-P13 was approved in 2013 by the European Medicines 
Agency (EMA) and, although it was developed to replicate 
with great accuracy the original product, there are minor 
distinctions in manufacturing steps in the production line and in 
the manufacturing process [132]-[133]-[134]-[135]. 
4.2.3. Subtypes of marketing innovation 
Considering the definitions of Kotler and Armstrong [136], the 
main task of marketing is "to achieve profitable growth for the 
company" [137]. Consequently, marketing groups must be able 
to identify, evaluate and select market opportunities, in addition 
to formulating strategies to capture these opportunities. 
Marketing among pharmaceutical companies is often regulated 
by public sector through restricted access to physicians and the 
nature of information disseminated to physicians given current 
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concerns [138]-[139]-[140]. In some cases, abuse can lead to 
fines as well as negatively impacting on future reimbursement 
negotiations [141]. Other mechanisms include advertising in 
magazines and congresses, lobbying, sponsoring physicians to 
attend congresses as well as direct payments to physicians 
[142]-[143]-[144]. 
The use of the internet for information and even for direct 
sales to consumers can be seen as a marketing radical 
innovation. The internet benefits individuals who could feel 
constrained and, through anonymity, privacy and convenience 
that the internet provides, users can obtain information about 
symptoms and be motivated to seek medical help [145]. The 
internet can also be used by healthcare providers to stimulate 
improved management of patients with non-communicable 
diseases especially where adherence to lifestyle changes and 
medicine use is a concern [146]. 
The Internet can also be used as a potent information and 
sales tool to promote the use of medicines. However, many 
authors express concern about the "cyberchondriacs" 
generation [145]. There are also concerns where companies are 
now offering services to assess the genetic profile of patients 
but without sufficient evidence to support the findings [147]. 
France has been one of the only countries to ban such activities 
[147]. The internet also brings facilities such as online 
pharmacies and sites known as "No Prescription Web Sites" 
(NPWs) where it is possible to buy prescription drugs without 
prescription, which favors self-medication [145]. 
In a semi-radical approach, through direct marketing, there 
was a new polarization in pharmaceutical industry marketing 
by sending detailers to see physicians [148]. Pressures for 
increased return on investment in new therapeutic substances, 
or even financial return due to possible shortened life cycles, 
new marketing strategies, distribution and commercialization 
have now been employed. This includes direct to consumer 
advertising and building over-the-counter sales through the 
internet [148]. An example is the repositioning of terbinafine 
antifungal. A failure was reported in communication between 
physicians, who believed onychomycosis was more a cosmetic 
issue and did not take the disease seriously. Patients took this 
disease more seriously, but who were reluctant to discuss the 
matter with their physician. Faced with this, the pharmaceutical 
company redirected its campaign for greater awareness with 
advertisements to the consumer via the internet, highlighting 
the need for medical treatment, while medical advertising 
highlighted the concern of patients. This generated immediate 
results, increasing the sales [149]. 
The effervescent paracetamol tablet indicates an innovative 
action more about commercialization than product, since it is 
based on sales stimulation of sales due to the development of a 
faster when compared with oral tablets [150]. This 
repositioning is configured as an incremental innovation. 
4.2.4. Subtypes of organizational innovation  
Culture and organizational methods can also lead to improved 
economic performance when applied to quality, 
communication, information and learning. Management 
measures can make the organization more effective and 
efficient. Development of radical tools and methods in an 
organization can considerably influence efficiency in 
management and financial returns for the company. 
Organizational innovations are based on new methods‟ creation 
within the organization that provide an application for new 
knowledge, skills, devices and instruments to better target, 
measure, encourage and monitor actions, in order to make the 
organization more competitive. 
In the past, pharmaceutical companies were dedicated more 
to improve patients' lives but ate the same time, generate profit 
to meet shareholders' needs and fund new research. However, 
their philosophy has undergone a significant cultural change 
over time. This ideological shift, demonstrated by the 
responsibility of increasing profits and investor returns, has 
directly impacted on corporate culture, with this goal now seen 
as essential [151]. This is seen by Kessel [151] who now argues 
that "medicine‟s ethics from the industrial pharmaceutical point 
of view has been replaced by the ethics of successful business". 
The supreme loyalty of corporations is now not primarily 
directed at patients and their doctors, but at shareholders. The 
adjustment of the traditional business model away from trying 
to improve patients‟ lives has suffered from shareholders‟ 
pressure to intensify financial results. 
In this scenario, patients' needs became secondary due the 
business emphasis, because companies are measured on how 
well their actions are negotiated and, as a consequence, 
administrative councils encourage this approach as a way to 
improve return on the investment [151]. This cultural change 
can be classified as a radical organizational novelty, since it 
deconstituted the previous cultural practice to concentrate on 
this one, essentially, leading to more prominent financial results 
through managerial practices. One example is the pricing of 
new cures for Hepatitis C where the cost-of-goods accounted 
for less than 0.1% of the initial price request leading to 
appreciable concerns of affordability across counties [67]-[68]-
[69]. Another example is the intense pressure now being placed 
on countries to fund new very expensive medicines in emotive 
disease areas such as cancer and orphan diseases with very 
little health gain [15]-[16]-[152]-[153]. As a result, patients 
with other diseases lose out within healthcare systems that seek 
to provide universal healthcare within finite resources. 
Validation in pharmaceutical industry can be characterized 
as a novel semi-radical organizational technique with the 
objective of demonstrating the reliability of procedures and 
processes in medicines‟ manufacture. The concept of validation 
was introduced by two FDA staff members in the mid-1970s, to 
reduce errors and quality deviations [154]. This was a novelty 
that established the standardization of how to demonstrate 
robustness in drug manufacturing practices. 
Another successful example of organizational change 
occurred in the 1940s, when Toyota, a Japanese automaker, 
developed and pioneered the application of the Lean concept, 
basing its performance model on a continuous flow [155]. The 
methodology was revolutionary and, therefore, radical in the 
automotive industry, changing the way the supply chain 
operates, how decisions are made and how people position 
themselves professionally. The Lean concept is mainly 
composed of the “just in time” system, which seeks a way to 
stabilize the production process and avoid overproduction 
[155]-[156]. The same principles have been applied to the 
pharmaceutical industry as an example of an imitative novelty 
already performed in other industries. Although the application 
has been similar to the system developed by the Japanese 
automobile segment, the methodology and the way of execution 
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can be adapted to the particularities of pharmaceutical segment 
with employment in different contexts and conferring a 
competitive advantage on companies that implemented it. 
These adaptations should be understood as incremental 
innovations. 
5. DISCUSSION AND CONCLUSION 
Innovation is widely employed in different context among 
pharmaceutical companies. However, their vast diversity makes 
it difficult to classify them. The inconsistencies in the framing 
and confusions with the application of the different terms used 
for classifying innovations may have contributed to the slow 
progression of knowledge and comparisons in these areas. 
Little has been published to date evaluating pharmaceutical 
innovations and their economic impact within the different 
classification factors of innovation. This study developed and 
analyzed the different potential innovation profiles among 
pharmaceutical companies from the types and subtypes of 
innovation. 
This involved the fusion of different classifications already 
delineated in the literature rather than the generation of new 
terms, exemplified by existing cases and techniques. In 
addition, profile stratification was created, which can be used 
for future frameworks and to fill this void, as well as to make a 
more didactic the identification of different innovative or 
imitative behaviors among pharmaceutical companies. The 
conceptual domain and its definitions are the key to contrast 
and compare different types of innovations. 
Radical and semi-radical innovations have the potential to 
offer appreciable profits and competitive advantage, but, in 
return, they require high risk, as well as potentially 
considerable company effort and resources [92]. Set as 
potentially risky items for the business, since not all innovation 
projects are successful and many investments may be lost due 
to innovation failure. This is especially evidenced in the 
pharmaceutical industry. However, risks are reduced by basic R 
& D being increasingly undertaken by universities, often with 
public monies. Some authors have estimated that over 80% of 
all basic research leading to new medicines is now undertaken 
by non-profit, university affiliated centres [157]. In addition, 
the cost of producing a new medicine is increasingly seen as 
nearer US$100 million rather than the often quoted figure of 
US$2.6billion [18]-[76]-[158].  
Pharmaceutical companies generally apply considerable 
R&D investments for radical and semi-radical innovations, 
especially for new medicines. The technological innovation can 
be extremely expensive and it can take a long time for new 
medicines to be introduced into the market given the increasing 
safety and other tests that now have to be performed for 
companies to receive a marketing authorization [159]. The 
failure rate in pharmaceutical R&D for new therapeutic 
molecules is high. According to Mazzucato and Tancioni 
[159], about 1 in 10 thousand chemical compounds reach the 
market. However, the increasing use of universities to 
undertake basic research may help to reduce this. In addition to 
the risk of failure due to possible deficiencies of their own 
innovation, there are other failures, such as the use, or 
innovation provider [160] that have a direct impact on a 
product‟s success.  
However, not all innovations are radical or semi-radical. 
Many are incremental and more process oriented. Hellwing 
[161] studying the competitive strategies of American and 
Japanese companies saw that Japanese companies are more 
concerned with incremental innovations, in learning from 
failures and focusing on productive process. Americans 
companies on the other hand were more concerned with 
novelty and radical innovations capable of discontinuing other 
products in the market place [162]. Companies that innovate 
successfully thrive at the expense of their less able competitors. 
That is why innovation is so fundamental to manufacturing 
industries, to their surviving and maintenance of market 
competitiveness. This is even more important with, as 
mentioned, an appreciable number of standard medicines are 
now available as low cost generics or biosimilars [7]. 
Allen and Hamilton [163] showed that less than 10% of 
innovations were new to the world.  Barbieri [162] believed 
that about two-thirds of innovations have a small impact and 
cost less than US $ 100,000.00. However, they contribute 
significantly to commercial success. Most of innovations were 
improvements, additions to existing products, repositioning of 
the product and cost reduction by replacing an input with 
another that serve the same purpose. So, smaller innovations 
should not be look down upon since they can promote 
efficiency and effectiveness, including how well the products 
were manufactured in accordance to specifications and how 
those specifications reflect what customers really value. 
Allied to creativity, imitations are a great source of 
improvement, from mastering the methods of obtaining the 
product or service. Evaluating an imitative innovation implies a 
distortion of technological dominance and continuous 
evolution. In this case, our conceptual proposal is that there are 
interfaces between pure imitation, imitative innovation and 
innovation. Regarding the elucidated differences, the common 
factor in literature is the agreement that a copy can‟t be 
underestimated, since it can confer technological differential 
and provide a competitive advantage. Moreover, what makes 
the imitation attractive is the power that it can generate from 
technology knowledge and creation, product, process, 
marketing, and organizational skills. According to Yu and 
researchers [118] "original innovation is the magic key for 
making success, and imitation is just the first stage". 
Consequently, in this point of view, imitative innovation is the 
way to promote and make technological diffusion in companies 
and in the world. 
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